However, conventional methods for identification of target expression are complicated: HER3 is not shedded at a sufficiently high amount to be a reliable biomarker in blood12 and biopsies are invasive procedures associated with risk of false negative results due to tumor heterogeneity. Here, ERBB3 is linked to neoplasm.